about
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexantThe role of the noradrenergic system in the exploration-exploitation trade-off: a psychopharmacological studyEffects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in manEffect of intrapulmonary tetrahydrocannabinol administration in humans.Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation.An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjectsThe central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.First in human study with a prodrug of galantamine: Improved benefit-risk ratio?The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.GSH-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study.Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.Pharmacodynamic response profiles of anxiolytic and sedative drugs.Reversal of Mecamylamine-Induced Effects in Healthy Subjects by Nicotine Receptor Agonists: Cognitive and (Electro)Physiological Responses.Pharmacological interactions between brivaracetam and ethanol in healthy males.Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.
P2860
Q28237266-FCE8AA0C-B6F8-4B85-932F-B63CBC6D80EFQ30497737-749F6A29-E14A-4E00-A7A4-D17293894E3BQ34448134-DFD58ABC-2617-48E3-A4A4-D1E9156FF5FEQ34783254-3AE728AF-D239-485C-80E4-27C8890A9DCDQ34982550-5BD65138-9E5D-4128-89BD-ED44A4F0C4BCQ34996934-4A755659-222E-42DE-8581-0E26175C7314Q35827155-039FDEE8-4D61-4EC2-A3BA-F79C5DE8CEB1Q37427922-C7BDA268-B116-49CC-BC29-0F5B0C34ECB7Q39784796-9B3A70C4-58B1-4197-9DBB-5637D1F3F856Q40086970-A00A048C-10C6-4918-A5CA-1EDB4E73F4A3Q40810950-5AF38A56-3649-448D-9B9F-485D8469012DQ40894855-BEF0F566-925E-4BA6-A63E-E0221D1B1BD3Q41634921-56578366-D761-47DE-9732-1FB87EF8E51DQ42283018-87557E77-74D3-45F3-8C4A-E9AB43D96F9AQ42689680-034DF123-407A-414F-864B-EA3A5BC14F80Q43168345-29E24AD7-27C5-43B0-A198-FF7BD97DFC5AQ44254954-19E13736-DE2F-41B5-9702-53A1EB028A30Q46404900-73B329E3-0FFC-489B-AA6B-3775D49BC638Q47547802-29B7C108-7BAC-4BA7-936C-76F5E0AA5A7DQ47746221-AF192F2C-309A-47A3-993E-3B53E8E3C0A5Q48178645-6281B8DF-7384-4711-B8CA-F33FFDE4FF31Q48271174-7E044694-DC7E-441F-B62A-B230ABCEAD40Q48596485-38D7E9AF-84AF-4E0F-BFB1-EF3303A33B7FQ48918400-82E610C7-CF18-4AC9-A03D-C8359AF91D74Q50262795-AA3A7067-24C2-4E78-90E0-BE6FCAC06328Q50666702-B44E3457-E853-4EBF-AB73-E52906C7F57AQ52646203-529AB3CD-99B2-45AE-9D5D-EA8683B29F1B
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Visual motor co-ordination and dynamic visual acuity.
@en
Visual motor co-ordination and dynamic visual acuity.
@nl
type
label
Visual motor co-ordination and dynamic visual acuity.
@en
Visual motor co-ordination and dynamic visual acuity.
@nl
prefLabel
Visual motor co-ordination and dynamic visual acuity.
@en
Visual motor co-ordination and dynamic visual acuity.
@nl
P2860
P1476
Visual motor co-ordination and dynamic visual acuity.
@en
P2093
Borland RG
Nicholson AN
P2860
P304
P356
10.1111/J.1365-2125.1984.TB02583.X
P407
P478
18 Suppl 1
P577
1984-01-01T00:00:00Z